IQVIA delivers industry‑leading early phase clinical trial solutions designed to accelerate confident, data‑driven decisions about a molecule’s potential. With a global network of 41 medically qualified Phase I units, access to more than 30 million electronic health records, and deep expertise across therapeutic, scientific, and regulatory domains, IQVIA supports everything from healthy volunteer studies to complex hybrid and patient‑based designs. Their integrated Phase I–IIa model, advanced predictive tools (including PK/PD modeling, biomarkers, and early QT analysis), and robust safety and quality oversight enable faster recruitment, optimized study execution, and seamless progression into later‑phase development. Over the past five years, IQVIA has delivered hundreds of early phase and first‑in‑human studies worldwide, helping sponsors accelerate timelines and advance molecules efficiently toward commercialization.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.
Improve the performance of your clinical trials with the power of the IQVIA CORE.
.svg){kind=icon}
